logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Lexogen Receives FFG Funding to Develop a Novel SARS-CoV-2 Test for Mass Screening

Lexogen Receives FFG Funding to Develop a Novel SARS-CoV-2 Test for Mass Screening

04/29/20, 1:17 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgvienna
Lexogen GmbH, a Vienna based Next-Generation Sequencing (NGS) and transcriptomics company, receives funding from the Austria Research Promotion Agency (FFG) for the development of a novel SARS-CoV-2 test method for mass screening.

Company Info

Company
Lexogen:
Location
vienna, illinois, united states
Additional Info
Established in 2007, Lexogen is a transcriptomics and Next-Generation Sequencing company, focusing on the development of innovative methods for RNA analysis. Its portfolio includes multiple innovative and well-established protocols for RNA sequencing sample preparation, external RNA spike-in controls, as well as bioinformatics tools and sequencing services. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, US.For more information about Lexogen visit www.lexogen.com and follow @lexogen.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.

Related people

JH

AH

JH

LH

BH

Sign up to get related executive contact information